Socma: House Bill Would Streamline FDA Drug Safety Efforts

Several U.S. lawmakers have introduced a bill that would result in more resources for FDA officials to conduct inspection of overseas drug ingredient manufacturers. The terms of the Generic Drug and Biosimilar User Fee Act have been a long-standing priority for Socma, which has a bulk pharmaceutical task force working on the issue. Socma says up to 40% of U.S. pharmaceuticals and up to 80% of drug intermediates are imported.   One of the goal’s of the bipartisan bill is to reduce the amount of time that it takes FDA to approve new drugs, from...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers